Illumina Q4 preliminary revenue rises 5%, beats analyst expectations

Illumina

13/01/2026 14:12

Overview

Genomics leader's preliminary Q4 revenue rises 5%, beating analyst expectations

Preliminary non-GAAP diluted EPS for Q4 ranges from $1.27 to $1.30

Fiscal year 2025 preliminary revenue remains flat compared to 2024

Outlook

Company did not provide specific guidance for future quarters or fiscal year

Result Drivers

EX-CHINA GROWTH - Co estimates 7% revenue growth excluding China in Q4

FLAT ANNUAL REVENUE - Fiscal year 2025 revenue estimated to remain flat compared to 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$1.16 bln
$1.10 bln (16 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 9 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Illumina Inc is $130.00, about 10.7% below its January 12 closing price of $145.55

The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 20 three months ago

Press Release: ID:nPn5NxZ72a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)